Oui, les groupes de soutien offrent un environnement d'encouragement et de partage d'expériences.
Groupes de soutienIntervention sociale
#5
Combien de temps dure un traitement pour le tabagisme ?
La durée du traitement varie, mais il est souvent recommandé de suivre un programme de plusieurs mois.
Durée du traitementPlan de traitement
Complications
5
#1
Quelles sont les complications du tabagisme ?
Les complications incluent des maladies cardiovasculaires, des cancers et des maladies respiratoires.
Maladies cardiovasculairesCancers
#2
Le tabagisme affecte-t-il la santé mentale ?
Oui, il est associé à des troubles de l'humeur, de l'anxiété et des problèmes de dépendance.
Santé mentaleTroubles de l'humeur
#3
Le tabagisme peut-il entraîner des problèmes de fertilité ?
Oui, il peut réduire la fertilité chez les hommes et les femmes, affectant la reproduction.
FertilitéSanté reproductive
#4
Les complications sont-elles réversibles ?
Certaines complications peuvent être réversibles avec l'arrêt du tabac, mais pas toutes.
RéversibilitéArrêt du tabac
#5
Le tabagisme augmente-t-il le risque d'infections ?
Oui, il affaiblit le système immunitaire, augmentant le risque d'infections respiratoires.
Infections respiratoiresSystème immunitaire
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque du tabagisme ?
Les facteurs incluent l'exposition à la fumée, l'hérédité et des influences sociales.
Facteurs de risqueExposition à la fumée
#2
L'âge influence-t-il le risque de tabagisme ?
Oui, les jeunes adultes sont plus susceptibles de commencer à fumer en raison de la pression sociale.
ÂgePression sociale
#3
Le stress est-il un facteur de risque ?
Oui, le stress peut inciter à fumer comme moyen de gestion des émotions et de l'anxiété.
StressGestion des émotions
#4
Les antécédents familiaux jouent-ils un rôle ?
Oui, avoir des membres de la famille fumeurs augmente le risque de développer une dépendance.
Antécédents familiauxDépendance au tabac
#5
Les publicités influencent-elles le tabagisme ?
Oui, les publicités peuvent normaliser le tabagisme et inciter les jeunes à commencer à fumer.
PublicitéInfluence sociale
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Trouble lié au tabagisme : Questions médicales les plus fréquentes",
"headline": "Trouble lié au tabagisme : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Trouble lié au tabagisme : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-31",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Trouble lié au tabagisme"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Troubles liés à une substance",
"url": "https://questionsmedicales.fr/mesh/D019966",
"about": {
"@type": "MedicalCondition",
"name": "Troubles liés à une substance",
"code": {
"@type": "MedicalCode",
"code": "D019966",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "F03.900"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Trouble lié au tabagisme",
"alternateName": "Tobacco Use Disorder",
"code": {
"@type": "MedicalCode",
"code": "D014029",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Joseph Guydish",
"url": "https://questionsmedicales.fr/author/Joseph%20Guydish",
"affiliation": {
"@type": "Organization",
"name": "Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, 3333 California St., Ste. 265, San Francisco, CA 94118, United States of America. Electronic address: joseph.guydish@ucsf.edu."
}
},
{
"@type": "Person",
"name": "Thao Le",
"url": "https://questionsmedicales.fr/author/Thao%20Le",
"affiliation": {
"@type": "Organization",
"name": "Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, 3333 California St., Ste. 265, San Francisco, CA 94118, United States of America. Electronic address: thao.le@ucsf.edu."
}
},
{
"@type": "Person",
"name": "Kevin Delucchi",
"url": "https://questionsmedicales.fr/author/Kevin%20Delucchi",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave., San Francisco, CA 94143, United States of America. Electronic address: kevin.delucchi@ucsf.edu."
}
},
{
"@type": "Person",
"name": "Guang-Heng Dong",
"url": "https://questionsmedicales.fr/author/Guang-Heng%20Dong",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychology, Yunnan Normal University, Kunming, Yunnan Province, PR China. Electronic address: dongguangheng@ynnu.edu.cn."
}
},
{
"@type": "Person",
"name": "Caravella McCuistian",
"url": "https://questionsmedicales.fr/author/Caravella%20McCuistian",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry and Behavioral Sciences, University of California, San Francisco 1001 Potrero Ave, San Francisco, CA 94110, United States. Electronic address: caravella.mccuistian@ucsf.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Immunophenotyping of pulmonary sarcomatoid carcinoma.",
"datePublished": "2022-10-20",
"url": "https://questionsmedicales.fr/article/36341325",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2022.976739"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immune infiltration and immunophenotyping in atrial fibrillation.",
"datePublished": "2023-01-04",
"url": "https://questionsmedicales.fr/article/36602538",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18632/aging.204470"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immunophenotypic characterization of acute leukemias in Bahia, Brazil.",
"datePublished": "2023-01-06",
"url": "https://questionsmedicales.fr/article/36629681",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.31744/einstein_journal/2023AO0117"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Immunophenotypic Profile of Healthy Human Bone Marrow.",
"datePublished": "2023-06-04",
"url": "https://questionsmedicales.fr/article/37481314",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cll.2023.04.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Describing IgA Myeloma: An Immunophenotypic and Molecular Approach.",
"datePublished": "2022-08-01",
"url": "https://questionsmedicales.fr/article/35882000",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Troubles mentaux",
"item": "https://questionsmedicales.fr/mesh/D001523"
},
{
"@type": "ListItem",
"position": 3,
"name": "Troubles liés à une substance",
"item": "https://questionsmedicales.fr/mesh/D019966"
},
{
"@type": "ListItem",
"position": 4,
"name": "Trouble lié au tabagisme",
"item": "https://questionsmedicales.fr/mesh/D014029"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Trouble lié au tabagisme - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Trouble lié au tabagisme",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Trouble lié au tabagisme",
"description": "Comment diagnostiquer un trouble lié au tabagisme ?\nQuels critères sont utilisés pour le diagnostic ?\nQui peut poser le diagnostic ?\nY a-t-il des tests spécifiques pour le diagnostic ?\nLe diagnostic peut-il être fait à distance ?",
"url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Immunophenotyping#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Trouble lié au tabagisme",
"description": "Quels sont les symptômes du trouble lié au tabagisme ?\nComment se manifeste le sevrage tabagique ?\nLe tabagisme peut-il affecter l'humeur ?\nY a-t-il des symptômes physiques associés ?\nLes symptômes varient-ils selon les individus ?",
"url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Immunophenotyping#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Trouble lié au tabagisme",
"description": "Comment prévenir le trouble lié au tabagisme ?\nLes campagnes anti-tabac sont-elles efficaces ?\nQuel rôle jouent les écoles dans la prévention ?\nLes lois anti-tabac aident-elles à réduire la consommation ?\nLes programmes de cessation sont-ils accessibles ?",
"url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Immunophenotyping#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Trouble lié au tabagisme",
"description": "Quels traitements sont disponibles pour le tabagisme ?\nLes médicaments sont-ils efficaces contre le tabagisme ?\nQu'est-ce que la thérapie comportementale ?\nLes groupes de soutien sont-ils utiles ?\nCombien de temps dure un traitement pour le tabagisme ?",
"url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Immunophenotyping#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Trouble lié au tabagisme",
"description": "Quelles sont les complications du tabagisme ?\nLe tabagisme affecte-t-il la santé mentale ?\nLe tabagisme peut-il entraîner des problèmes de fertilité ?\nLes complications sont-elles réversibles ?\nLe tabagisme augmente-t-il le risque d'infections ?",
"url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Immunophenotyping#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Trouble lié au tabagisme",
"description": "Quels sont les principaux facteurs de risque du tabagisme ?\nL'âge influence-t-il le risque de tabagisme ?\nLe stress est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nLes publicités influencent-elles le tabagisme ?",
"url": "https://questionsmedicales.fr/mesh/D014029?mesh_terms=Immunophenotyping#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un trouble lié au tabagisme ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation des habitudes de consommation et des symptômes de dépendance."
}
},
{
"@type": "Question",
"name": "Quels critères sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent la consommation régulière, le désir de réduire et les symptômes de sevrage."
}
},
{
"@type": "Question",
"name": "Qui peut poser le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un professionnel de santé, comme un médecin ou un psychologue, peut poser le diagnostic."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests spécifiques pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de tests spécifiques, le diagnostic est basé sur l'entretien clinique."
}
},
{
"@type": "Question",
"name": "Le diagnostic peut-il être fait à distance ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des consultations en ligne peuvent permettre d'évaluer les habitudes de consommation."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes du trouble lié au tabagisme ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent le besoin urgent de fumer, l'irritabilité et les symptômes de sevrage."
}
},
{
"@type": "Question",
"name": "Comment se manifeste le sevrage tabagique ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le sevrage peut provoquer anxiété, dépression, troubles du sommeil et fringales."
}
},
{
"@type": "Question",
"name": "Le tabagisme peut-il affecter l'humeur ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut entraîner des fluctuations d'humeur et des troubles émotionnels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes physiques associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme la toux, l'essoufflement et des douleurs thoraciques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la durée et de l'intensité de la consommation."
}
},
{
"@type": "Question",
"name": "Comment prévenir le trouble lié au tabagisme ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par l'éducation, la sensibilisation et des politiques anti-tabac efficaces."
}
},
{
"@type": "Question",
"name": "Les campagnes anti-tabac sont-elles efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sensibilisent le public aux dangers du tabagisme et encouragent l'arrêt."
}
},
{
"@type": "Question",
"name": "Quel rôle jouent les écoles dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les écoles peuvent éduquer les jeunes sur les dangers du tabac et promouvoir des modes de vie sains."
}
},
{
"@type": "Question",
"name": "Les lois anti-tabac aident-elles à réduire la consommation ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des lois strictes sur la vente et la consommation de tabac réduisent son usage."
}
},
{
"@type": "Question",
"name": "Les programmes de cessation sont-ils accessibles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux programmes de cessation sont disponibles dans les centres de santé et en ligne."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour le tabagisme ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent les substituts nicotiniques, les médicaments et la thérapie comportementale."
}
},
{
"@type": "Question",
"name": "Les médicaments sont-ils efficaces contre le tabagisme ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des médicaments comme la varénicline et le bupropion sont efficaces pour réduire le besoin de fumer."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que la thérapie comportementale ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est une approche qui aide à modifier les comportements liés à la consommation de tabac."
}
},
{
"@type": "Question",
"name": "Les groupes de soutien sont-ils utiles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les groupes de soutien offrent un environnement d'encouragement et de partage d'expériences."
}
},
{
"@type": "Question",
"name": "Combien de temps dure un traitement pour le tabagisme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée du traitement varie, mais il est souvent recommandé de suivre un programme de plusieurs mois."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications du tabagisme ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des maladies cardiovasculaires, des cancers et des maladies respiratoires."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il la santé mentale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est associé à des troubles de l'humeur, de l'anxiété et des problèmes de dépendance."
}
},
{
"@type": "Question",
"name": "Le tabagisme peut-il entraîner des problèmes de fertilité ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut réduire la fertilité chez les hommes et les femmes, affectant la reproduction."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec l'arrêt du tabac, mais pas toutes."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque d'infections ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il affaiblit le système immunitaire, augmentant le risque d'infections respiratoires."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du tabagisme ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition à la fumée, l'hérédité et des influences sociales."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de tabagisme ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes adultes sont plus susceptibles de commencer à fumer en raison de la pression sociale."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut inciter à fumer comme moyen de gestion des émotions et de l'anxiété."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir des membres de la famille fumeurs augmente le risque de développer une dépendance."
}
},
{
"@type": "Question",
"name": "Les publicités influencent-elles le tabagisme ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les publicités peuvent normaliser le tabagisme et inciter les jeunes à commencer à fumer."
}
}
]
}
]
}
Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, 3333 California St., Ste. 265, San Francisco, CA 94118, United States of America. Electronic address: joseph.guydish@ucsf.edu.
Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, 3333 California St., Ste. 265, San Francisco, CA 94118, United States of America. Electronic address: thao.le@ucsf.edu.
Department of Psychiatry, University of California San Francisco, 401 Parnassus Ave., San Francisco, CA 94143, United States of America. Electronic address: kevin.delucchi@ucsf.edu.
Department of Psychiatry and Behavioral Sciences, University of California, San Francisco 1001 Potrero Ave, San Francisco, CA 94110, United States. Electronic address: caravella.mccuistian@ucsf.edu.
Philip R. Lee Institute for Health Policy Studies, University of California San Francisco, 3333 California St., Ste. 265, San Francisco, CA, 94118, United States. Electronic address: kwinoja.kapiteni@ucsf.edu.
OHSU/PSU School of Public Health, Oregon Health and Sciences University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239-3098, United States. Electronic address: drbarbaracampbell@earthlink.net.
Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor, Michigan; School of Nursing, University of Michigan, Ann Arbor, Michigan.
Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor, Michigan; School of Nursing, University of Michigan, Ann Arbor, Michigan; Addiction Center, Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.
Previous studies have suggested that patients with pulmonary sarcomatoid carcinoma (PSC)may benefit from immune checkpoint inhibitors (ICIs); however, relevant data are lacking. This study aimed to es...
A retrospective analysis of pathologically confirmed PSC cases from two centers was performed from January 2009 to May 2021. According to the infiltration of CD8+ T cells in different spatial regions,...
A total of 32 patients with PSC were included in the final analysis. Of these patients, 65.6% (21/32), 15.6% (5/32), and 18.8% (6/32) were classified as immune-inflamed, immune-excluded, and immune-de...
Patients with PSC are characterized by immune-inflamed type and type I (PD-L1+/CD8+, adaptive immune resistance), explaining the intrinsic reasons for their high response rate to immunotherapy....
Atrial fibrillation (AF) is a relatively common arrhythmia in clinical practice. Although significant progress has been achieved in the treatment of AF and its associated complications, research on AF...
To characterize the immunophenotypic profile of acute leukemias in the population of the state of Bahia, Brazil....
This is a descriptive, retrospective study. From 2014 to 2018, 796 new cases of acute leukemia were evaluated. The data were obtained from analysis of reports and records of tests performed by flow cy...
Most cases were diagnosed as acute myeloid leukemia and 42.7% as acute lymphoblastic leukemia. Significant differences were found in expression of markers in acute leukemias when age groups were compa...
Significant differences were found as to several antigens when comparing adults and children, and these findings may contribute to future studies correlating the phenotypic profile to genetic characte...
Flow cytometry enables multiparametric characterization of hematopoietic cell immunophenotype. Deviations from normal immunophenotypic patterns comprise a cardinal feature of many hematopoietic neopla...
Plasma cell myeloma (PCM) is defined as a clonal disease of terminally differentiated plasma cells that secrete immunoglobulin. The biologic underpinnings of IgA-type multiple myeloma's (IgAMM) aggres...
ASD reconstructions are a major, sterile traumatic insult, likely causing perturbations to the immune systems. The immune response to surgery is associated with outcomes. The purpose of this study was...
Consecutive patients undergoing ASD surgery were approached and enrolled. Peripheral blood was drawn before incision, 4 h after, and 24 h after incision. Blood was stabilized and comprehensive flow cy...
Thirteen patients were enrolled; 11(85%) F, 65.4 years (± 7.5), surgical duration 418 ± 83 min, EBL 1928 ± 1253 mL. Hierarchical clustering and PCA found consistent time from incision-dependent change...
Despite surgery and patient heterogeneity, we identified an immune signature associated with the sterile trauma of ASD surgery. Circulating leukocyte populations change in composition and signaling pr...
We aimed to provide an autophagy-related signature to seek immunophenotyping biomarkers in osteoarthritis (OA)....
Microarray expression profiling of OA subchondral bone samples and screening of an autophagy database for autophagy-related differentially expressed genes (au-DEGs) between OA and normal samples were ...
We screened 754 au-DEGs between OA and control samples, and co-expression networks were constructed using au-DEGs. Three OA-related autophagy hub genes (HSPA5, HSP90AA1, and ITPKB) were identified. Ba...
Three autophagy-related markers of OA were identified using bioinformatics methods, and these markers may be useful for the autophagy-related immunophenotyping of OA. The present data may facilitate t...
Prompt diagnosis of acute promyelocytic leukemia (APL) is critical for patient care. In this study, we aimed to characterize the immunophenotype of APL and explore immunophenotypic difference between ...
Eighty-five cases were collected, including 47 APL, 26 NPM1-mutated acute myeloid leukemia (AML) and 12 KMT2A-rearranged AML with an APL-like immunophenotype. Immunophenotypes were analyzed using flow...
APL showed four distinct patterns (designated a-d) based on CD45/SSC plots. Blasts in patterns a-c showed high side scatter, whereas blasts in pattern d had low side scatter and were located in the tr...
APL and its immunophenotypic mimics share some immunophenotypic similarities but can be distinguished by CD2, CD13, CD34, CD64, and MPO....
Acute myeloid leukemia (AML) with RAM immunophenotype is a distinct subtype of AML, as described by the Children's Oncology Group (COG), with characteristic morphological and immunophenotypic properti...
Seven cases with the characteristic RAM immunophenotype were identified in this retrospective analysis of newly diagnosed pediatric AML cases from January 2019 to December 2021. Herein, we have critic...
Of 302 cases of pediatric AML (age <18 years), seven cases (2.3%) with the distinct RAM phenotype were observed, with age ranging from 9 months to 5 years. Two patients were misdiagnosed earlier as sm...
AML with RAM immunophenotype, a distinct form of pediatric AML with a poor prognosis, may pose a diagnostic challenge if presented as a soft tissue mass. A comprehensive immunophenotypic evaluation, i...
Tγδ large granular lymphocyte leukemia (Tγδ LGLL) is a rare lymphoproliferative disease, scantily described in literature. A deep-analysis, in an initial cohort of 9 Tγδ LGLL compared to 23 healthy co...